Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia

American Journal of Kidney Diseases

Volumn 66, Issue 2, 2015, Pages 196-205

  Charytan, David M ^a   Fishbane, Steven ^b   Malyszko, Jolanta ^c   McCullough, Peter A ^d,e   Goldsmith, David ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e The Heart Hospital   (United States)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

anemia; bone mineral axis; cardiovascular disease (CVD); chronic kidney disease (CKD); end stage renal disease (ESRD); erythropoietin (EPO); fibroblast growth factor 23 (FGF 23); heart failure (HF); Index Words Cardiorenal syndrome (CRS); iron; phosphate; renal dysfunction; review; vitamin D

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM; CINACALCET; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FERRIC CARBOXYMALTOSE; FIBROBLAST GROWTH FACTOR 23; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; SEVELAMER; SPIRONOLACTONE; CALCIFEDIOL; CALCITRIOL; FIBROBLAST GROWTH FACTOR; PHOSPHATE;

ANEMIA; BONE MINERAL; CARDIORENAL SYNDROME; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; ERYTHROPOIETIN DEFICIENCY; HEART FAILURE; HORMONE DEFICIENCY; HORMONE SYNTHESIS; HUMAN; IRON DEFICIENCY ANEMIA; IRON METABOLISM; MOLECULAR PATHOLOGY; NONHUMAN; PHOSPHATE METABOLISM; PROTEIN FUNCTION; REVIEW; VITAMIN D METABOLISM; BONE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM;

ANEMIA; BONE AND BONES; CALCIFEDIOL; CALCITRIOL; CALCIUM; CARDIO-RENAL SYNDROME; CARDIOVASCULAR DISEASES; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTORS; HUMANS; IRON; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84936143283     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2014.12.016     Document Type: Article

References (104)

1. A.A. House, I. Anand, R. Bellomo, and et al. Definition and classification of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference Nephrol Dial Transplant 25 5 2010 1416 1420
2. Minino AM. Death in the United States, 2011. NCHS data brief, no 115. Hyattsville, MD; 2013. http://www.cdc.gov/nchs/data/databriefs/db115.htm. Accessed November 6, 2013.
3. D.L. Hoyert, and J. Xu Deaths: preliminary data for 2011 Natl Vital Stat Rep 61 2012 1 52
4. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, and et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 17 2003 2154 2169
5. N.S. Anavekar, J.J. McMurray, E.J. Velazquez, and et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 13 2004 1285 1295
6. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 13 2004 1296 1305
7. A.J. Collins, R.N. Foley, B. Chavers, and et al. US Renal Data System 2013 annual data report Am J Kidney Dis 63 1 suppl 1 2014 e1 e420
8. Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet: general information and national estimates on chronic kidney disease in the United States, 2010. Atlanta, GA; 2010. http://www.cdc.gov/diabetes/pubs/pdf/kidney-factsheet.pdf. Accessed November 6, 2013.
9. P.A. McCullough, S. Steigerwalt, K. Tolia, and et al. Cardiovascular disease in chronic kidney disease: data from the Kidney Early Evaluation Program (KEEP) Curr Diab Rep 11 1 2011 47 55
10. A. Lindner, B. Charra, D.J. Sherrard, and B.H. Scribner Accelerated atherosclerosis in prolonged maintenance hemodialysis N Engl J Med 290 13 1974 697 701
11. P. Muntner, J. He, B.C. Astor, A.R. Folsom, and J. Coresh Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study J Am Soc Nephrol 16 2 2005 529 538
12. P. Muntner, L.L. Hamm, J.W. Kusek, J. Chen, P.K. Whelton, and J. He The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease Ann Intern Med 140 1 2004 9 17
13. J.J. Sim, S.K. Bhandari, N. Smith, and et al. Phosphorus and risk of renal failure in subjects with normal renal function Am J Med 126 4 2013 311 318
14. D.A. Goodkin, J.L. Bragg-Gresham, K.G. Koenig, and et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS) J Am Soc Nephrol 14 12 2003 3270 3277
15. J.P. Lash, A.S. Go, L.J. Appel, and et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function Clin J Am Soc Nephrol 4 8 2009 1302 1311
16. K. Damman, M.A. Valente, A.A. Voors, C.M. O'Connor, D.J. van Veldhuisen, and H.L. Hillege Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis Eur Heart J 35 7 2014 455 469
17. J.S. Bock, and S.S. Gottlieb Cardiorenal syndrome: new perspectives Circulation 121 23 2010 2592 2600
18. C.P. Kovesdy, and L.D. Quarles The role of fibroblast growth factor-23 in cardiorenal syndrome Nephron Clin Pract 123 3-4 2013 194 201
19. K. Kiattisunthorn, and S.M. Moe Chronic kidney disease-mineral bone disorder (CKD-MBD) IBMS BoneKey 7 2010 447 457
20. E. Beutler Hemochromatosis: genetics and pathophysiology Annu Rev Med 57 2006 331 347
21. J.L. Babitt, and H.Y. Lin Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD Am J Kidney Dis 55 4 2010 726 741
22. J. Malyszko, and M. Mysliwiec Hepcidin in anemia and inflammation in chronic kidney disease Kidney Blood Press Res 30 1 2007 15 30
23. K. van der Putten, B. Braam, K.E. Jie, and C.A. Gaillard Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure Nat Clin Pract Nephrol 4 1 2008 47 57
24. K. van der Putten, K.E. Jie, D. van den Broek, and et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients Eur J Heart Fail 12 9 2010 943 950
25. E.V. Khankin, W.P. Mutter, H. Tamez, H.T. Yuan, S.A. Karumanchi, and R. Thadhani Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease PLoS One 5 2 2010 e9246
26. Z. Kiss, C. Ambrus, C. Almasi, and et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis Nephron Clin Pract 117 4 2011 c373 c378
27. M. Wagner, A. Alam, J. Zimmermann, and et al. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease Clin J Am Soc Nephrol 6 7 2011 1573 1579
28. S. Mohammed, S. Knoll, A. van Amburg III, and P.A. Mennes Cefotetan-induced hemolytic anemia causing severe hypophosphatemia Am J Hematol 46 4 1994 369 370
29. M. Steiner, B. Steiner, S. Wilhelm, M. Freund, and P. Schuff-Werner Severe hypophosphatemia during hematopoietic reconstitution after allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 25 9 2000 1015 1016
30. D.B. Van Wyck, A. Mangione, J. Morrison, P.E. Hadley, J.A. Jehle, and L.T. Goodnough Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial Transfusion 49 12 2009 2719 2728
31. T. Sanai, N. Oochi, M. Okada, K. Imamura, S. Okuda, and M. Iida Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats J Lab Clin Med 146 1 2005 25 29
32. Y. Shimizu, Y. Tada, M. Yamauchi, and et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia Bone 45 4 2009 814 816
33. B.J. Schouten, P.J. Hunt, J.H. Livesey, C.M. Frampton, and S.G. Soule FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study J Clin Endocrinol Metab 94 7 2009 2332 2337
34. M. Prats, R. Font, C. Garcia, C. Cabre, M. Jariod, and A.M. Vea Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study BMC Nephrol 14 1 2013 167
35. S.M. Deger, Y. Erten, O.T. Pasaoglu, and et al. The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients Clin Exp Nephrol 17 3 2013 416 423
36. Y. Takeda, H. Komaba, S. Goto, and et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients Am J Nephrol 33 5 2011 421 426
37. J. Bacchetta, J.J. Zaritsky, J.L. Sea, and et al. Suppression of iron-regulatory hepcidin by vitamin D J Am Soc Nephrol 25 3 2014 564 572
38. I. Six, J. Maizel, F.C. Barreto, and et al. Effects of phosphate on vascular function under normal conditions and influence of the uraemic state Cardiovasc Res 96 1 2012 130 139
39. G.S. Di Marco, M. Konig, C. Stock, and et al. High phosphate directly affects endothelial function by downregulating annexin II Kidney Int 83 2 2013 213 222
40. O.M. Kuro Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism Nat Rev Nephrol 9 11 2013 650 660
41. R.C. Shroff, R. McNair, J.N. Skepper, and et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification J Am Soc Nephrol 21 1 2010 103 112
42. M. Kanbay, D. Goldsmith, A. Akcay, and A. Covic Phosphate - the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review Blood Purif 27 2 2009 220 230
43. C. Ronco, and M. Cozzolino Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes Heart Fail Rev 17 2 2012 211 220
44. K. Kienreich, A. Tomaschitz, N. Verheyen, and et al. Vitamin D and cardiovascular disease Nutrients 5 8 2013 3005 3021
45. K.R. Neves, F.G. Graciolli, L.M. dos Reis, C.A. Pasqualucci, R.M. Moyses, and V. Jorgetti Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure Kidney Int 66 6 2004 2237 2244
46. M.R. Custodio, M.K. Koike, K.R. Neves, and et al. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system Nephrol Dial Transplant 27 4 2012 1437 1445
47. M.W. Merx, C. Schafer, R. Westenfeld, and et al. Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice J Am Soc Nephrol 16 11 2005 3357 3364
48. P. Regmi, B. Malla, P. Gyawali, and et al. Product of serum calcium and phosphorus (Ca x PO4) as predictor of cardiovascular disease risk in predialysis patients Clin Biochem 47 1-2 2014 77 81
49. G.A. Block, T.E. Hulbert-Shearon, N.W. Levin, and F.K. Port Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 4 1998 607 617
50. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, and G.M. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 8 2004 2208 2218
51. A. Covic, P. Kothawala, M. Bernal, S. Robbins, A. Chalian, and D. Goldsmith Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease Nephrol Dial Transplant 24 5 2009 1506 1523
52. C. Faul, A.P. Amaral, B. Oskouei, and et al. FGF23 induces left ventricular hypertrophy J Clin Invest 121 11 2011 4393 4408
53. S. Panizo, S. Barrio-Vazquez, M. Naves-Diaz, and et al. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis Nephrol Dial Transplant 28 11 2013 2735 2744
54. A. Rahman, S. Hershey, S. Ahmed, K. Nibbelink, and R.U. Simpson Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice J Steroid Biochem Mol Biol 103 3-5 2007 416 419
55. R.U. Simpson, S.H. Hershey, and K.A. Nibbelink Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse J Steroid Biochem Mol Biol 103 3-5 2007 521 524
56. H. Ogata, E. Ritz, G. Odoni, K. Amann, and S.R. Orth Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors J Am Soc Nephrol 14 4 2003 959 967
57. K. Amann, E. Ritz, G. Wiest, G. Klaus, and G. Mall A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia J Am Soc Nephrol 4 10 1994 1814 1819
58. E. Rodriguez-Ayala, M. Avila-Diaz, E. Foyo-Niembro, D. Amato, E. Ramirez-San-Juan, and R. Paniagua Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone Nephron Physiol 103 3 2006 p112 p118
59. B. Dai, V. David, A. Martin, and et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model PLoS One 7 9 2012 e44161
60. A.R. Patange, R.P. Valentini, M.P. Gothe, W. Du, and M.D. Pettersen Vitamin D deficiency is associated with increased left ventricular mass and diastolic dysfunction in children with chronic kidney disease Pediatr Cardiol 34 3 2013 536 542
61. A.J. van Ballegooijen, M. Visser, B. Kestenbaum, and et al. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study) Am J Cardiol 111 3 2013 418 424
62. B. Kestenbaum, R. Katz, I. de Boer, and et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults J Am Coll Cardiol 58 14 2011 1433 1441
63. O.M. Gutierrez, J.L. Januzzi, T. Isakova, and et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease Circulation 119 19 2009 2545 2552
64. A. Unsal, S. Kose Budak, Y. Koc, and et al. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease Kidney Blood Press Res 36 1 2012 55 64
65. J.J. Scialla, H. Xie, M. Rahman, and et al. Fibroblast growth factor-23 and cardiovascular events in CKD J Am Soc Nephrol 25 2 2014 349 360
66. H.F. Groenveld, J.L. Januzzi, K. Damman, and et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis J Am Coll Cardiol 52 10 2008 818 827
67. R.N. Foley, P.S. Parfrey, J.D. Harnett, G.M. Kent, D.C. Murray, and P.E. Barre The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease Am J Kidney Dis 28 1 1996 53 61
68. A. Levin, C.R. Thompson, J. Ethier, and et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin Am J Kidney Dis 34 1 1999 125 134
69. T.B. Horwich, G.C. Fonarow, M.A. Hamilton, W.R. MacLellan, and J. Borenstein Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure J Am Coll Cardiol 39 11 2002 1780 1786
70. J. Comin-Colet, C. Enjuanes, G. Gonzalez, and et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status Eur J Heart Fail 15 10 2013 1164 1172
71. D. Goldstein, B. Felzen, M. Youdim, R. Lotan, and O. Binah Experimental iron deficiency in rats: mechanical and electrophysiological alterations in the cardiac muscle Clin Sci (Lond) 91 2 1996 233 239
72. K. Rakusan, N. Cicutti, and F. Kolar Effect of anemia on cardiac function, microvascular structure, and capillary hematocrit in rat hearts Am J Physiol Heart Circ Physiol 280 3 2001 H1407 H1414
73. G. Olivetti, F. Quaini, C. Lagrasta, and et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats Am J Pathol 141 1 1992 227 239
74. I.S. Anand, Y. Chandrashekhar, G.S. Wander, and L.S. Chawla Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia J Am Coll Cardiol 25 6 1995 1402 1407
75. I.S. Anand, Y. Chandrashekhar, R. Ferrari, P.A. Poole-Wilson, and P.C. Harris Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones Br Heart J 70 4 1993 357 362
76. D.S. Silverberg, D. Wexler, A. Iaina, and D. Schwartz Correction of iron deficiency in the cardiorenal syndrome Int J Nephrol 2011 2011 365301
77. S. Lele, S. Shah, P.A. McCullough, and M. Rajapurkar Serum catalytic iron as a novel biomarker of vascular injury in acute coronary syndromes Eurointervention 5 3 2009 336 342
78. K. Akrawinthawong, M.K. Shaw, J. Kachner, and et al. Urine catalytic iron and neutrophil gelatinase-associated lipocalin as companion early markers of acute kidney injury after cardiac surgery: a prospective pilot study Cardiorenal Med 3 1 2013 7 16
79. M.P. Kooistra, S. Kersting, I. Gosriwatana, and et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion Eur J Clin Invest 32 suppl 1 2002 36 41
80. D.B. Kell Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases BMC Med Genomics 2 2009 2
81. R. El Hasnaoui-Saadani, D. Marchant, A. Pichon, and et al. Epo deficiency alters cardiac adaptation to chronic hypoxia Respir Physiol Neurobiol 186 2 2013 146 154
82. G.L. Wright, P. Hanlon, K. Amin, C. Steenbergen, E. Murphy, and M.O. Arcasoy Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury FASEB J 18 9 2004 1031 1033
83. J.C. Ayus, A.S. Go, F. Valderrabano, and et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL Kidney Int 68 2 2005 788 795
84. J. Silberberg, N. Racine, P. Barre, and A.D. Sniderman Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin Can J Cardiol 6 1 1990 1 4
85. T. Hayashi, A. Suzuki, T. Shoji, and et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure Am J Kidney Dis 35 2 2000 250 256
86. P.S. Parfrey, M. Lauve, D. Latremouille-Viau, and P. Lefebvre Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis Clin J Am Soc Nephrol 4 4 2009 755 762
87. P.A. McCullough, H.X. Barnhart, J.K. Inrig, and et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease Am J Nephrol 37 6 2013 549 558
88. R.V. Shah, S. McNulty, C.M. O'Connor, G.M. Felker, E. Braunwald, and M.M. Givertz Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure Am Heart J 164 6 2012 862 868
89. R.D. Kociol, S.E. McNulty, A.F. Hernandez, and et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure Circ Heart Fail 6 2 2013 240 245
90. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) Am J Cardiol 78 8 1996 902 907
91. B. Pitt, F. Zannad, W.J. Remme, and et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 10 1999 709 717
92. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, and G.F. Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease Cochrane Database Syst Rev 3 2009 CD007004
93. H.A. Cooper, D.L. Dries, C.E. Davis, Y.L. Shen, and M.J. Domanski Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction Circulation 100 12 1999 1311 1315
94. G.M. Chertow, S.K. Burke, and P. Raggi Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 1 2002 245 252
95. W. Qunibi, M. Moustafa, L.R. Muenz, and et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study Am J Kidney Dis 51 6 2008 952 965
96. D.V. Barreto, C. Barreto Fde, A.B. de Carvalho, and et al. Phosphate binder impact on bone remodeling and coronary calcification - results from the BRiC study Nephron Clin Pract 110 4 2008 c273 c283
97. W.L. St Peter, J. Liu, E. Weinhandl, and Q. Fan A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data Am J Kidney Dis 51 3 2008 445 454
98. H. Tamez, C. Zoccali, D. Packham, and et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease Am Heart J 164 6 2012 902 909 e902
99. R. Thadhani, E. Appelbaum, Y. Pritchett, and et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial JAMA 307 7 2012 674 684
100. A.Y. Wang, F. Fang, J. Chan, and et al. Effect of paricalcitol on left ventricular mass and function in CKD - the OPERA trial J Am Soc Nephrol 25 1 2014 175 186
101. G.M. Chertow, G.A. Block, R. Correa-Rotter, and et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis N Engl J Med 367 26 2012 2482 2494
102. S.D. Anker, J. Comin Colet, G. Filippatos, and et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 25 2009 2436 2448
103. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency [published online ahead of print August 31, 2014]. Eur Heart J. http://dx.doi.org.ezp-prod1.hul.harvard.edu/10.1093/eurheartj/ehu385.
104. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, and et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 21 2009 2019 2032